Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Obinutuzumab in Systemic Sclerosis: a Phase II, Randomized, Double-blinded Versus Placebo-controlled Trial"

NCT07842523 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT07842523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07842523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Obinutuzumab in Systemic Sclerosis: a Phase II, Randomized, Double-blinded Versus Placebo-controlled Trial"
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
June 30, 2030
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis in adults